Does severe teratozoospermia affect blastocyst formation, live birth rate, and other clinical outcome parameters in ICSI cycles?

Size: px
Start display at page:

Download "Does severe teratozoospermia affect blastocyst formation, live birth rate, and other clinical outcome parameters in ICSI cycles?"

Transcription

1 Does severe teratozoospermia affect blastocyst formation, live birth rate, and other clinical outcome parameters in ICSI cycles? Dan B. French, M.D., a Edmund S. Sabanegh, Jr., M.D., a James Goldfarb, M.D., b and Nina Desai, Ph.D., H.C.L.D. b a Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland; and b Department of Obstetrics and Gynecology, Cleveland Clinic Fertility Center, Beachwood, Ohio Objective: To determine if strict morphology correlates with outcome parameters in couples undergoing intracytoplasmic sperm injection (ICSI). Design: Retrospective review. Setting: Academic nonprofit IVF center. Patient(s): Couples undergoing IVF/ICSI. Intervention(s): In vitro fertilization and ICSI. Main Outcome Measure(s): Samples were evaluated for total sperm count, motlity, progression, and morphology using Kruger s strict criteria. The ICSI cycle outcome parameters included fertilization, clinical pregnancy, implantation, live birth, and blastulation rates and blastocyst quality. Result(s): Fertilization rates were high (74% 77%), and clinical pregnancy rates ranged from 60% (subgroup with 0% normal sperm) to 56% (subgroup with R7% normal forms). The highest pregnancy and live birth rates were observed in eggs fertilized with sperm from specimens with the most severe teratozoospermia. The blastulation rate was similar among subgroups. The percentage of high-quality blastocysts was significantly greater in the severely teratozoospermic patients compared with patients with R5% normal sperm (37% vs. 28%). This is likely because in the lower morphology subgroups, female factors are less prevalent and the primary infertility problem is male factor. Conclusion(s): These data suggest that we reconsider the diagnostic value of strict morphology in assisted reproductive technology cycles involving ICSI. Sperm morphology assessed by Kruger s strict criteria had little prognostic value in ICSI cycle outcomes. Sperm morphology did not appear to influence blastocyst development or blastocyst morphology. Microscopic selection of sperm with normal morphology during the ICSI procedure allowed excellent outcomes even in samples with severe teratozoospermia. (Fertil Steril Ò 2009;-:- -. Ó2009 by American Society for Reproductive Medicine.) Key Words: Sperm morphology, in vitro fertilization, ICSI, blastocyst development Morphologic evaluation of spermatozoa is an integral part of the semen analysis work-up for infertility. Kruger et al. proposed that sperm classification on the basis of stricter morphologic criteria could be useful in predicting successful fertilization (1). In a meta-analysis of outcomes in intrauterine insemination cycles, a trend toward better pregnancy rates was indicated when sperm morphology was >4% (2). Severe teratozoospermia with <4% normal forms in the semen sample was also associated with poorer fertilization outcomes during IVF (3, 4). A meta-analysis of sperm morphology and IVF outcome parameters in 49 different studies using conventional IVF similarly concluded that sperm morphology assessment may be valuable as a diagnostic tool in evaluating male infertility (5). This, however, is still an area of Received June 5, 2008; revised October 27, 2008; accepted October 29, D.F. has nothing to disclose. E.S. has nothing to disclose. J.G. has nothing to disclose. N.D. has nothing to disclose. Reprint requests: Nina Desai, Ph.D., H.C.L.D., Cleveland Clinic Fertility Center, Suite 220 South Building, Cedar Rd., Beachwood, OH (FAX: ; desain@ccf.org). considerable debate. Numerous other reports suggest that abnormal morphology is not an accurate predictor of pregnancy or cycle outcome parameters (6 11). The relevance of the assessment of sperm morphology of the overall semen sample as it pertains to IVF with intracytoplasmic sperm injection (ICSI) is even less clear. Oocyte fertilization through ICSI circumvents many problems, such as poor motility, poor zona binding, and poor acrosome reaction, which are frequently found in association with specimens having abnormal sperm morphology. Multiple studies have shown that with IVF/ICSI, semen samples with poor Kruger morphology have similar fertilization and pregnancy rates to those with normal morphology (8, 9, 11 13). McKenzie et al. (14) analyzed ICSI outcomes in a subset of severe teratozoospermic patients with 0% normal sperm. They concluded that sperm morphology had little predictive value regarding fertilization and pregnancy outcome in men undergoing ICSI for severe teratozoospermia. Some of the studies analyzing morphology and ICSI outcomes were small and not all of them included live birth rates or examined detailed subsets of patients across the spectrum of morphologic impairment /09/$36.00 Fertility and Sterility â Vol. -, No. -, doi: /j.fertnstert Copyright ª2009 American Society for Reproductive Medicine, Published by Elsevier Inc.

2 The role of paternal factors in embryonic development, as well as the effect of the ICSI procedure itself remains controversial. Several studies have suggested that ICSI-derived embryos have reduced developmental capacity (15 18). In contrast, others using severely teratozoospermic sperm have seen no difference in blastulation rates with ICSI (19, 20). The objective of the present study was to determine if critical assessment of sperm morphology during the pre-ivf semen analysis correlated with ICSI cycle outcome parameters. We analyzed the impact of severe teratozoospermia on fertilization, embryonic development to the blastocyst stage, and pregnancy. To our knowledge, this is the first large ICSI series that examines live birth outcomes in sperm morphology subgroups ranging from severely teratozoospermic to normal. This information should help us to gain a better understanding of paternal effect on embryonic development and the influence of the ICSI technique itself on embryonic development. MATERIALS AND METHODS Patients The IVF cycles with ICSI were performed at the Cleveland Clinic Fertility Center from January 2004 to December 2006 and retrospectively analyzed. Day 5 transfers accounted for 65 cycles, and these were not included in the present analysis. During the time interval encompassed by this study, ICSI was the laboratory s preferred method of fertilization unless the patient specifically requested standard insemination. Cases involving some or all conventional IVF were eliminated (5%). Cycles in which semen specimens had insufficient sperm (usually < /ml) to allow morphologic assessment were also excluded. Only women <37 years of age were included in the analysis, to minimize the contribution of maternal age as a confounding variable. As a result, 1,074 ICSI cycles were available for analysis. Patients were divided into subgroups based on sperm morphology. Sperm Morphology Assessment Semen samples were evaluated for total count, percentage motile sperm, forward progression, and sperm morphology. Sperm were stained using Diff-Quik (Dade Behring, Newark, Delaware). Sperm morphology was assessed using Kruger s strict criteria (21). A total of 100 sperm were graded at each evaluation and percentage normal forms determined. Sperm morphology grading was performed by one of two andrology technicians, and uniformity of grading between the two andrology technicians was routinely monitored using control slides. IVF Procedure Down-regulation with leuprolide acetate (Lupron; TAP Pharmaceuticals, Lake Forest, IL) followed by ovulation induction with gonadotropins was the primary stimulation protocol used. Oocytes were recovered by transvaginal aspiration of follicles under ultrasound guidance. Oocytes were cultured in microdrops of human tubal fluid (HTF) medium (LifeGlobal, Guilford, CT) supplemented with 10 mg/ml human serum albumin (Cooper Surgical, Trumball, CT) under an oil overlay. Culture dishes were incubated at 37 C with 5.5% CO 2. Mature oocytes were fertilized by ICSI 3 4 h after the retrieval. Fertilization check was performed h after the ICSI procedure. Normally fertilized zygotes were subsequently moved to microdrops containing HTF medium with 10% synthetic serum substitute (SSS, Irvine, CA) and cultured for an additional 2 days. Embryo transfer was performed on day 3 under ultrasound guidance using a Wallace catheter. Embryo selection for day 3 transfer was based on morphologic parameters. Embryos were graded on the basis of cell number, regularity of blastomeres, good blastomere expansion, fragmentation level, and signs of embryonic compaction. Spare embryos not transfered or frozen on day 3 were kept in culture and frozen at the blastocyst stage. Pregnancy testing was performed 15 days after the embryo transfer. Clinical pregnancy was confirmed by the presence of a fetal heart on ultrasonic examination at 6 8 weeks of pregnancy. Data Collection and Statistical Analysis Cycle outcome data was collected under Institutional Review Board approval from the IVF lab data registry. The primary outcome measures tabulated were fertilization rate, blastocyst formation, embryos transfered, pregnancy rate, and implantation rate. The implantation rate was calculated by dividing the number of fetal heart tones by the total number of embryos transfered. Multiple pregnancy and live birth rates were also monitored. Patients were stratified into groups based on their sperm morphology assessment. Using Kruger s strict criteria, eight subgroups were analyzed: 0%, 1%, 2%, 3%, 4%, 5% 7%, and >7% normal sperm morphology. Differences in outcome measures between groups were compared using the Chi-squared test and the Student t test. P values of <.05 were considered to be statistically significant. RESULTS A total of 1,074 ICSI cycles were included in this analysis. The semen characteristics in each morphology subgroup are portrayed in Figure 1. The percentage of patients in each morphology group with either a compromised sperm count or overall motility of <40% is shown. As might be expected, patients in the more teratozoospermic morphology subgroups (<4% normal sperm) also exhibited deficits in other sperm parameters. Table 1 depicts the relationship between sperm morphology based on Kruger s strict assessment and cycle outcome parameters. Fertilization rates were high regardless of sperm morphologic parameters. Intracytoplasmic sperm injection resulted in 74% 77% of oocytes being fertilized. The average 2 French et al. Severe teratospermia and ICSI clinical outcomes Vol. -, No. -,

3 FIGURE 1 Percentage of patients with concentration and motility impairment among morphology subgroups. Sperm Parameters in Morphology Sub Groups 35 Percent of patients Count <=10 mill/ml Motility <40% 5 0 0% 1% 2% 3% 4% 5-7% >7% Sperm morphology French. Severe teratospermia and ICSI clinical outcomes. Fertil Steril number of oocytes retrieved, mature oocytes for injection, number of embryos transfered, and patient age were similar across morphology subgroups. Clinical pregnancy outcomes were excellent, ranging from 60% in the subgroup with the most severe teratospermia (0% normal sperm) to 56% in the patient set with the highest percentage normal spermatozoa. The implantation rate per embryo transferred ranged from 31% to 41% (Table 1). The variations in the main outcome parameters of fertilization, pregnancy, and embryo implantation did not correlate with sperm morphology. Our data suggest that in cycles in which oocyte fertilization is mediated through ICSI, poor sperm morphology at the time of semen analysis has no significant impact on clinical outcome parameters. This is further shown by the fact that the highest pregnancy and live birth rates were observed in the group of patient eggs fertilized with sperm from specimens with the most severe teratozoospermia, i.e., the subgroup with 0% normal sperm morphology. Culturing the spare embryos not transferred on day 3 for an additional 3 days gave us the opportunity to further observe development to the blastocyst stage and to assess the quality of the blastocysts. Table 1 summarizes both the percentage of blastocysts formed and the percentage of high-quality blastocysts deemed to be suitable for freezing based on morphology. Blastocyst quality assessment was based on the degree of expansion, presence of an adequate cell number, and differentiation of the inner cell mass and the trophectoderm. The blastulation rate was not different among the different sperm morphology subgroups (P¼.07). We did, however, find that the percentage of high-quality blastocysts was significantly greater in the severely teratozoospermic patients with 0% normal sperm compared with patients with R5% normal sperm (37% vs. 28%; P<.005). To better understand these data, we looked at patient diagnosis across the different morphology subgroups. Figure 2 depicts the percentage of patients with each diagnosis for each sperm morphology subgroup. From these data it would appear that in the lower morphology subgroups, female factors are less prevalent and the primary infertility problem is male factor. In the 0% 1% normal sperm subgroup, approximately 38% of couples had male factor as their primary diagnosis. At the other extreme, in the subgroup with >7% normal sperm, female factors such as ovulatory dysfunction, tubal factor, polycystic ovary, and endometriosis were the primary diagnosis in 45% of couples. Another 41% of patients had unexplained infertility. Only 14% of couples in this subgroup had male factor as the primary diagnosis based on low sperm count, motility, or progression. Severe teratozoospermia did not negatively affect ICSI success. The live birth rate per transfer ranged from 44% to 56%. The observed variation in live birth rate among the different morphology subgroups was not found to be significant. The miscarriage rate was 4% 5% for all but one of the subgroups (Table 1). Among the 774 live births, only four birth defects were reported to the clinic three were cardiac problems and one was classified as genetic. Follow-up beyond the immediate neonatal period was not conducted. DISCUSSION This study represents the first large ICSI series to analyze embryonic development, pregnancy outcomes, and live birth rates in different sperm morphology subgroups based on Kruger s classification system. Stratification of data in this manner allowed for evaluation and comparison of outcomes based on degree of teratozoospermia. In this study, fertilization, implantation, pregnancy, and live birth rates were not Fertility and Sterility â 3

4 TABLE 1 Kruger strict morphology and ICSI cycle outcome. % normal sperm morphology 0% 1% 2% 3% 4% 5% 7% >7% Transfers Maternal age No. of oocytes No. of oocytes injected Fertilization rate 75% 75% 77% 77% 74% 76% 77% No. of embryos transfered Blastulation rate 50% 43% 44% 47% 41% 42% 45% with spare embryos Blastocysts of high 37% a 29% 26% 31% 27% 28% 29% quality suitable for freezing Clinical pregnancy 60% 59% 56% 49% 57% 54% 56% rate Implantation rate 36% 39% 32% 31% 41% 34% 33% Live birth 56% 54% 47% 44% 52% 49% 52% rate per transfer Miscarriage rate 4% 5% 9% 5% 5% 5% 4% Total deliveries Singleton Twins Triplets a Significantly different from other morphology subgroups (P<.05). French. Severe teratospermia and ICSI clinical outcomes. Fertil Steril statistically different among various morphology subgroups, even including those with severe teratozoospermia. Moreover, a negative paternal effect on blastocyst development as a result of ICSI and/or use of sperm from patients with severe teratozoospermia was not observed. Although strict sperm morphology may affect fertilization rates in intrauterine insemination (2) and cycles with conventional IVF insemination (3), this association is not seen when ICSI is used. Numerous studies, including the present work, support the conclusion that poor sperm morphology on pre- IVF semen analysis using Kruger s strict criteria does not correlate to either poor fertilization and/or pregnancy rates in ICSI cycles (8, 9, 11 14). The most likely explanation for this is that during ICSI the embryologist can microscopically select individual sperm that appear morphologically normal, from even the most impaired specimens. Thus, fertilization occurs with sperm that may not be representative of the sperm population within the entire sample, making the initial semen morphology assessment irrelevant. This concept has been taken to the subcellular level in new techniques such as intracytoplasmic morphologically selected sperm injection and motile sperm organellar morphology examination (MSOME). In these techniques, investigators select sperm for ICSI using a highpower 1,000 objective to magnify and allow more critical assessment of sperm morphology. Sperm nucleus morphology by the MSOME method has positively correlated with fertilization and pregnancy rates (22, 23). Experience with these methods, however, is too limited to draw definitive conclusions regarding efficacy and potential for augmenting the birth rate of healthy infants after ICSI. Looking at how sperm morphology correlates with sperm function, DNA damage, and chromosomal status may help in understanding the prognostic value of strict morphology assessment. Data from several studies suggest that abnormal sperm morphology does not necessarily translate into 4 French et al. Severe teratospermia and ICSI clinical outcomes Vol. -, No. -,

5 FIGURE 2 Etiology of infertility by sperm morphology subgroups. 100% Patient Diagnosis in Sperm Morphology Subgroups 80% % of patients 60% 40% 20% Other Endometriosis Ovulatory Tubal Unexplained Male Factor 0% 0% 1% 2% 3% 4% 5-7% >7% % Normal Forms French. Severe teratospermia and ICSI clinical outcomes. Fertil Steril abnormal chromosomal content (24 26). Celik-Ozenci et al. (27), using fluorescent in situ hybridization, found that 10% of sperm with disomic nuclei were categorized as normal by strict morphology. Sperm morphology defects may serve more as a barrier to reaching and penetrating the oocyte zona. Sperm DNA fragmentation may affect cycle outcome, embryonic development, and blastocyst formation (28 31). However, no clear relationship has been shown between morphologic attributes of sperm and degree of DNA damage (32 34). Despite its efficacy as a tool for oocyte fertilization, there is continued concern that the use of the ICSI technique eliminates any opportunity for natural selection of the sperm that will ultimately fertilize the oocyte. Although the risk of birth defects in children conceived through ART is increased over that of natural conception, the fear that ICSI will result in higher rates of major birth defects compared with conventional IVF has not been substantiated by current data. A recent meta-analysis showed a 30% 40% increased risk of major birth defects with assisted reproduction (either IVF or ICSI) compared with natural conception (35). A study comparing 1,462 children conceived through IVF or intrauterine insemination with 8,422 naturally conceived children found the incidence of birth defects to be 6.2% with IVF or IUI versus 4.4% with natural conception. However, no difference was seen in the risk of birth defects when comparing traditional IVF and ICSI (36). A meta-analysis of four studies with a total of 5,395 children born after ICSI confirms a lack of statistically significant increase in birth defects with ICSI compared with conventional IVF (37). Another concern has been that the ICSI process itself causes damage to imprinted genes (38, 39). These methylated genes are particularly susceptible to damage and are labeled such that only the maternal or paternal copy is expressed. It has been suggested that the ICSI process itself disrupts these fragile genes, leading to their loss of function and in turn manifestation of imprinting disorders, such as Angelman syndrome and Beckwith-Wiedemann syndrome. Among children with Beckwith-Weidemann syndrome, 4.6% were identified as having been conceived by ART (mostly ICSI), which was an increase from the baseline rate of 0.76% of live births resulting from ART in the general population (40). Although no such cases were noted in the present series, developmental disturbances are clearly more difficult to track than congenital anomalies. Paternal effect on blastocyst quality has been a question of great interest. Janny and Menezo (41) suggested a correlation between impaired semen parameters and reduced blastocyst development in conventional IVF cycles. Others have reported poorer blastocyst development in embryos derived from ICSI versus conventional IVF (15). Miller and Smith (16) observed that a greater number of ICSI-derived embryos arrested at the 5 8-cell stage, corresponding to the time of paternal genome activation. Moreover, fewer ICSI-derived embryos (14%) developed to blastocyst compared with IVF embryos (28%). Kihaile et al. (18) compared sibling oocytes inseminated or injected with sperm from patients with severe teratozoospermia. Despite a higher fertilization rate, development was compromised in the ICSI group, with fewer embryos progressing to the blastocyst stage. Both groups had severe teratospermia, suggesting that something inherent in the ICSI process itself affects blastocyst development. Contradictory results were obtained by Van Landuyt et al. (20), who found that sibling oocytes from ICSI versus Fertility and Sterility â 5

6 conventional IVF showed similar rates of embryonic development and blastocyst formation. The present findings did not indicate a negative effect of the ICSI technique on blastocyst formation. We achieved a blastulation rate of between 41% and 50% among the different sperm morphology subgroups using ICSI. We did not observe a correlation between severe teratozoopsermia and poorer blastocyst quality. A significantly greater percentage of high-quality blastocysts was obtained in the most severely teratospermic subgroup, with 0% normal forms, probably owing to a lower contribution of female factor infertility in this group. These data suggest that Kruger s strict morphology was not useful in predicting either the rate of blastocyst development or the morphologic characteristics of the resulting blastocysts in ICSI cycles. We acknowledge several limitations of this report. The contribution of female diagnosis to cycle outcome could not be completely assessed. Even though the most important variable affecting oocyte quality, maternal age, was controlled for in our data set, we recognize that genetic factors and ovarian response to stimulation also play significant roles. The relationship between sperm morphology, ICSI, and birth defects could not be adequately addressed in this investigation. A more controlled study with ICSI and IVF of sibling oocytes is needed to confirm our observation that the intracytoplasmic sperm injection technique itself was not disruptive to subsequent normal embryonic development and live birth rate. Also, long-term follow-up at multiple IVF centers and a larger live birth data set will be necessary to truly assess the impact of ICSI on birth defects and imprinting disorders. Finally, this study excluded the subgroup of men with semen densities of under 1 million, owing to logistical problems performing morphology assessments on small numbers of spermatozoa. Further study of this subgroup is certainly warranted. Teratozoospermia combined with severe oligozoospermia could potentially affect ICSI outcomes, by reducing the likehood of locating a normal sperm for injection. In conclusion, the present data suggest that, in ICSI cycles, Kruger strict morphology is not predictive of fertilization rates, clinical pregnancy rates, blastulation, or blastocyst quality. Microscopic selection of sperm with normal morphology during the ICSI procedure allowed excellent outcomes even in samples with severe teratozoospermia. The live birth rate was similarly unaffected by sperm morphology parameters. Kruger strict criteria, as paternal factor, and/or the ICSI procedure itself did not appear to negatively impact blastocyst development or pregnancy outcome. REFERENCES 1. Kruger TF, Menkveld R, Stander FS, Lombard CJ, Van der Merwe JP, van Zyl JA, et al. Sperm morphologic features as a prognostic factor in in vitro fertilization. Fertil Steril 1986;46: Van Waart J, Kruger TF, Lombard CJ, Ombelet W. Predictive value of normal sperm morphology in intrauterine insemination (IUI): a structured literature review. Hum Reprod Update 2001;7: Kruger TF, Acosta AA, Simmons KF, Swanson RJ, Matta JF, Oehninger S. Predictive value of abnormal sperm morphology in in vitro fertilization. Fertil Steril 1988;49: Grow DR, Oehninger S, Seltman HJ, Toner JP, Swanson RJ, Kruger TF, et al. Sperm morphology as diagnosed by strict criteria: probing the impact of teratozoospermia on fertilization rate and pregnancy outcome in a large in vitro fertilization population. Fertil Steril 1994;62: Coetzee K, Kruge TF, Lombard CJ. Predictive value of normal sperm morphology: a structured literature review. Hum Reprod Update 1998;4: Check JH, Adelson HG, Schubert BR, Bollendorf A. Evaluation of sperm morphology using Kruger s strict criteria. Arch Androl 1992;28: Check ML, Bollendorf A, Check JH, Katsoff D. Reevaluation of the clinical importance of evaluating sperm morphology using strict criteria. Arch Androl 2002;48: Svalander P, Jakobsson AH, Forsberg AS, Bengtsson AC, Wikland M. The outcome of intracytoplasmic sperm injection is unrelated to strict criteria sperm morphology. Hum Reprod 1996;11: Lundin K, Soderlund B, Hamberger L. The relationship between sperm morphology and rates of fertilization, pregnancy and spontaneous abortion in an in-vitro fertilization/intracytoplasmic sperm injection programme. Hum Reprod 1997;12: Robinson JN, Lockwood GM, Dokras A, Egan DM, Nicholson SC, Ross C, et al. Does isolated teratozoospermia affect performance in invitro fertilization and embryo transfer? Hum Reprod 1994;9: Keegan BR, Barton S, Sanchez X, Berkeley AS, Krey LC, Grifo J. Isolated teratozoospermia does not affect in vitro fertilization outcome and is not an indication for intracytoplasmic sperm injection. Fertil Steril 2007;88: Nagy ZP, Liu J, Joris H, Verheyen G, Tournaye H, Camus M, et al. The result of intracytoplasmic sperm injection is not related to any of the three basic sperm parameters. Hum Reprod 1995;10: Kupker W, al-hasani S, Schulze W, Kuhnel W, Schill T, Felberbaum R, et al. Morphology in intracytoplasmic sperm injection: preliminary results. J Assist Reprod Genet 1995;12: McKenzie LJ, Kovanci E, Amato P, Cisneros P, Lamb D, Carson SA. Pregnancy outcome of in vitro fertilization/intracytoplasmic sperm injection with profound teratospermia. Fertil Steril 2004;82: Dumoulin JC, Coonen E, Bras M, van Wissen LC, Ignoul-Vanvuchelen R, Bergers-Jansen JM, et al. Comparison of in-vitro development of embryos originating from either conventional in-vitro fertilization or intracytoplasmic sperm injection. Hum Reprod 2000;15: Miller JE, Smith TT. The effect of intracytoplasmic sperm injection and semen parameters on blastocyst development in vitro. Hum Reprod 2001;16: Shoukir Y, Chardonnens D, Campana A, Sakkas D. Blastocyst development from supernumerary embryos after intracytoplasmic sperm injection: a paternal influence? Hum Reprod 1998;13: Kihaile PE, Misumi J, Hirotsuru K, Kumasako Y, Kisanga RE, Utsunomiya T. Comparison of sibling oocyte outcomes after intracytoplasmic sperm injection and in vitro fertilization in severe teratozoospermic patients in the first cycle. Int J Androl 2003;26: Oehninger S, Kruger TF, Simon T, Jones D, Mayer J, Lanzendorf S, et al. A comparative analysis of embryo implantation potential in patients with severe teratozoospermia undergoing in-vitro fertilization with a high insemination concentration or intracytoplasmic sperm injection. Hum Reprod 1996;11: Van Landuyt L, De Vos A, Joris H, Verheyen G, Devroey P, Van Steirteghem A. Blastocyst formation in in vitro fertilization versus intracytoplasmic sperm injection cycles: influence of the fertilization procedure. Fertil Steril 2005;83: Kruger TF, Acosta AA, Simmons KF, Swanson RJ, Matta JF, Veeck LL, et al. New method of evaluating sperm morphology with predictive value for human in vitro fertilization. Urology 1987;30: Bartoov B, Berkovitz A, Eltes F, Kogosowski A, Menezo Y, Barak Y. Real-time fine morphology of motile human sperm cells is associated with IVF-ICSI outcome. J Androl 2002;23: French et al. Severe teratospermia and ICSI clinical outcomes Vol. -, No. -,

7 23. Berkovitz A, Eltes F, Yaari S, Katz N, Barr I, Fishman A, et al. The morphological normalcy of the sperm nucleus and pregnancy rate of intracytoplasmic injection with morphologically selected sperm. Hum Reprod 2005;20: Martin RH, Rademaker A. The relationship between sperm chromosomal abnormalities and sperm morphology in humans. Mutat Res 1988;207: Rosenbusch B, Strehler E, Sterzik K. Cytogenetics of human spermatozoa: correlations with sperm morphology and age of fertile men. Fertil Steril 1992;58: Viville S, Mollard R, Bach ML, Falquet C, Gerlinger P, Warter S. Do morphological anomalies reflect chromosomal aneuploidies? Case report. Hum Reprod 2000;15: Celik-Ozenci C, Jakab A, Kovacs T, Catalanotti J, Demir R, Bray- Ward P, et al. Sperm selection for ICSI: shape properties do not predict the absence or presence of numerical chromosomal aberrations. Hum Reprod 2004;19: Muriel L, Garrido N, Fernandez JL, Remohi J, Pellicer A, de los Santos MJ, et al. Value of the sperm deoxyribonucleic acid fragmentation level, as measured by the sperm chromatin dispersion test, in the outcome of in vitro fertilization and intracytoplasmic sperm injection. Fertil Steril 2006;85: Seli E, Gardner DK, Schoolcraft WB, Moffatt O, Sakkas D. Extent of nuclear DNA damage in ejaculated spermatozoa impacts on blastocyst development after in vitro fertilization. Fertil Steril 2004;82: Virro MR, Larson-Cook KL, Evenson DP. Sperm chromatin structure assay (SCSA) parameters are related to fertilization, blastocyst development, and ongoing pregnancy in in vitro fertilization and intracytoplasmic sperm injection cycles. Fertil Steril 2004;81: Tarozzi N, Bizzaro D, Flamigni C, Borini A. Clinical relevance of sperm DNA damage in assisted reproduction. Reprod Biomed Online 2007;14: Evenson DP, Jost LK, Marshall D, Zinaman MJ, Clegg E, Purvis K, et al. Utility of the sperm chromatin structure assay as a diagnostic and prognostic tool in the human fertility clinic. Hum Reprod 1999;14: Trisini AT, Singh NP, Duty SM, Hauser R. Relationship between human semen parameters and deoxyribonucleic acid damage assessed by the neutral comet assay. Fertil Steril 2004;82: Donnelly ET, Steele EK, McClure N, Lewis SE. Assessment of DNA integrity and morphology of ejaculated spermatozoa from fertile and infertile men before and after cryopreservation. Hum Reprod 2001;16: Hansen M, Bower C, Milne E, de Klerk N, Kurinczuk JJ. Assisted reproductive technologies and the risk of birth defects a systematic review. Hum Reprod 2005;20: Olson CK, Keppler-Noreuil KM, Romitti PA, Budelier WT, Ryan G, Sparks AE, et al. In vitro fertilization is associated with an increase in major birth defects. Fertil Steril 2005;84: Lie RT, Lyngstadaas A, Orstavik KH, Bakketeig LS, Jacobsen G, Tanbo T. Birth defects in children conceived by ICSI compared with children conceived by other IVF-methods; a meta-analysis. Int J Epidemiol 2005;34: Kurinczuk JJ. Safety issues in assisted reproduction technology. From theory to reality just what are the data telling us about ICSI offspring health and future fertility and should we be concerned? Hum Reprod 2003;18: Young LE, Fernandes K, McEvoy TG, Butterwith SC, Gutierrez CG, Carolan C, et al. Epigenetic change in IGF2R is associated with fetal overgrowth after sheep embryo culture. Nat Genet 2001;27: DeBaun MR, Niemitz EL, Feinberg AP. Association of in vitro fertilization with Beckwith-Wiedemann syndrome and epigenetic alterations of LIT1 and H19. Am J Hum Genet 2003;72: Janny L, Menezo YJ. Evidence for a strong paternal effect on human preimplantation embryo development and blastocyst formation. Mol Reprod Dev 1994;38: Fertility and Sterility â 7

Minimum standards for ICSI use, screening, patient information and follow-up in WA fertility clinics. January 2006

Minimum standards for ICSI use, screening, patient information and follow-up in WA fertility clinics. January 2006 Minimum standards for ICSI use, screening, patient information and follow-up in WA fertility clinics January 2006 1. BACKGROUND ICSI has been shown to be effective for male factor infertility and it also

More information

Assisted Reproductive Technologies at IGO

Assisted Reproductive Technologies at IGO 9339 Genesee Avenue, Suite 220 San Diego, CA 92121 858 455 7520 Assisted Reproductive Technologies at IGO Although IGO no longer operates an IVF laboratory or program as such, we work closely with area

More information

Influence of strict sperm morphology on the results of classic in vitro fertilization

Influence of strict sperm morphology on the results of classic in vitro fertilization ORIGINAL ARTICLE Vol. 38 (4): 519-528, July - August, 2012 Influence of strict sperm morphology on the results of classic in vitro fertilization Milton Ghirelli-Filho, Françoise Elia Mizrahi, Antonio Carlos

More information

Topic: Male Factor Infertility

Topic: Male Factor Infertility Topic: Male Factor Infertility Topic Overview: Male Factor Infertility Comparisons of pregnancy rates at insemination based on total motile sperm counts from the 1999 and 21 World Health Organization (WHO)

More information

In - Vitro Fertilization Handbook

In - Vitro Fertilization Handbook In - Vitro Fertilization Handbook William F. Ziegler, D.O. Medical Director Scott Kratka, ELD, TS Embryology Laboratory Director Lauren F. Lucas, P.A.-C, M.S. Physician Assistant Frances Cerniak, R.N.

More information

Preimplantation Genetic Diagnosis (PGD) in Western Australia

Preimplantation Genetic Diagnosis (PGD) in Western Australia Preimplantation Genetic Diagnosis (PGD) in Western Australia Human somatic cells have 46 chromosomes each, made up of the 23 chromosomes provided by the egg and the sperm cell from each parent. Each chromosome

More information

Assisted reproductive technologies (ART) in Canada: 2011 results from the Canadian ART Register

Assisted reproductive technologies (ART) in Canada: 2011 results from the Canadian ART Register 1 Assisted reproductive technologies (ART) in Canada: 2011 results from the Canadian ART Register Joanne Gunby, M.Sc. CARTR Co-ordinator Email: gunbyj@mcmaster.ca Supported by the IVF Directors Group of

More information

Welcome to chapter 2. The following chapter is called "Indications For IVF". The author is Dr Kamini A. Rao.

Welcome to chapter 2. The following chapter is called Indications For IVF. The author is Dr Kamini A. Rao. Welcome to chapter 2. The following chapter is called "Indications For IVF". The author is Dr Kamini A. Rao. The indications for an IVF treatment have increased since the birth of the first IVF baby. The

More information

AGE & FERTILITY: Effective Evaluation & Treatment I. LANE WONG, MD, FACOG. www.hopefertilitycenter.com www.hopeivf.com

AGE & FERTILITY: Effective Evaluation & Treatment I. LANE WONG, MD, FACOG. www.hopefertilitycenter.com www.hopeivf.com Page 1 of 6 AGE & FERTILITY: Effective Evaluation & Treatment I. LANE WONG, MD, FACOG. www.hopefertilitycenter.com www.hopeivf.com Age has a profound effect on female fertility. This is common knowledge,

More information

Infertility Services Medical Policy For University of Vermont Medical Center and Central Vermont Medical Center employer groups

Infertility Services Medical Policy For University of Vermont Medical Center and Central Vermont Medical Center employer groups Infertility Services Medical Policy For University of Vermont Medical Center and Central Vermont Medical Center employer groups File name: Infertility Services File code: UM.REPRO.01 Last Review: 02/2016

More information

Recent Progress in In Vitro Fertilization and Intracytoplasmic Sperm Injection Technologies in Japan

Recent Progress in In Vitro Fertilization and Intracytoplasmic Sperm Injection Technologies in Japan Research and Reviews Recent Progress in In Vitro Fertilization and Intracytoplasmic Sperm Injection Technologies in Japan JMAJ 52(1): 29 33, 2009 Kaoru YANAGIDA* 1 Abstract The three basic pillars of fertility

More information

Symposium on RECENT ADVANCES IN ASSISTED REPRODUCTIVE TECHNOLOGY

Symposium on RECENT ADVANCES IN ASSISTED REPRODUCTIVE TECHNOLOGY Symposium on RECENT ADVANCES IN ASSISTED REPRODUCTIVE TECHNOLOGY Dr Niel Senewirathne Senior Consultant of Obstetrician & Gynaecologist De zoyza Maternity Hospita 1 ART - IVF & ICSI 2 Infertility No pregnancy

More information

Risks and complications of assisted conception

Risks and complications of assisted conception Risks and complications of assisted conception August 005 Richard Kennedy British Fertility Society Factsheet www.fertility.org.uk No medical treatment is entirely free from risk and infertility treatment

More information

ASSISTED REPRODUCTIVE TECHNOLOGIES (ART)

ASSISTED REPRODUCTIVE TECHNOLOGIES (ART) ASSISTED REPRODUCTIVE TECHNOLOGIES (ART) Dr. Herve Lucas, MD, PhD, Biologist, Andrologist Dr. Taher Elbarbary, MD Gynecologist-Obstetrician Definitions of Assisted Reproductive Technologies Techniques

More information

East and North Hertfordshire CCG Fertility treatment and referral criteria for tertiary level assisted conception. December 2014

East and North Hertfordshire CCG Fertility treatment and referral criteria for tertiary level assisted conception. December 2014 East and North Hertfordshire CCG Fertility treatment and referral criteria for tertiary level assisted conception December 2014 1 1. Introduction This policy sets out the entitlement and service that will

More information

Ehlers-Danlos Syndrome Fertility Issues. Objectives

Ehlers-Danlos Syndrome Fertility Issues. Objectives Ehlers-Danlos Syndrome Fertility Issues Baltimore Inner Harbor Independence Day Brad Hurst, M.D. Professor Reproductive Endocrinology Carolinas Medical Center - Charlotte, North Carolina Objectives Determine

More information

Consent to Perform Preimplantation Genetic Screening (PGS) using. Comparative Genomic Hybridization (acgh) or Next Generation Sequencing (NGS)

Consent to Perform Preimplantation Genetic Screening (PGS) using. Comparative Genomic Hybridization (acgh) or Next Generation Sequencing (NGS) Consent to Perform Preimplantation Genetic Screening (PGS) using Array Comparative Genomic Hybridization (acgh ) or Next Generation Sequencing (NGS) Purpose The purpose of Preimplantation Genetic Screening

More information

In Vitro Fertilization (IVF) Page 1 of 11

In Vitro Fertilization (IVF) Page 1 of 11 In Vitro Fertilization (IVF) Page 1 of 11 This document is a part of your informed consent process. Both partners should read the entire document carefully. In vitro fertilization (IVF) is a treatment

More information

Guide to IVF Laboratory Results

Guide to IVF Laboratory Results Guide to IVF Laboratory Results PACIFIC CENTRE FOR REPRODUCTIVE MEDICINE 500-4601 Canada Way, Burnaby BC V5G 4X7 LAB-416-20140122-1 The following information will guide you through what results to expect

More information

Clinical Policy Committee

Clinical Policy Committee Northern, Eastern and Western Devon Clinical Commissioning Group South Devon and Torbay Clinical Commissioning Group Clinical Policy Committee Commissioning policy: Assisted Conception Fertility assessment

More information

REI Pearls: Pitfalls of Genetic Testing in Miscarriage

REI Pearls: Pitfalls of Genetic Testing in Miscarriage The Skinny: Genetic testing of miscarriage tissue is controversial and some people question if testing is helpful or not. This summary will: 1) outline the arguments for and against genetic testing; 2)

More information

A POWERFUL IN VITRO FERTILIZATION

A POWERFUL IN VITRO FERTILIZATION A POWERFUL During the past 50 years technological advances in the field of bovine reproduction have led to some dramatic changes in the way cattle look, reproduce, perform, and even taste. Artificial Insemination

More information

Artificial insemination

Artificial insemination Artificial insemination What is involved? Artificial insemination is an assisted reproduction technique that consists of inserting laboratory-treated spermatozoa into the woman s uterus or cervical canal.

More information

LEUKODYSTROPHY GENETICS AND REPRODUCTIVE OPTIONS FOR AFFECTED FAMILIES. Leila Jamal, ScM Kennedy Krieger Institute, Baltimore MD

LEUKODYSTROPHY GENETICS AND REPRODUCTIVE OPTIONS FOR AFFECTED FAMILIES. Leila Jamal, ScM Kennedy Krieger Institute, Baltimore MD LEUKODYSTROPHY GENETICS AND REPRODUCTIVE OPTIONS FOR AFFECTED FAMILIES Leila Jamal, ScM Kennedy Krieger Institute, Baltimore MD 2 Outline Genetics 101: Basic Concepts and Myth Busting Inheritance Patterns

More information

Assisted reproductive technologies in Canada: 2005 results from the Canadian Assisted Reproductive Technologies Register

Assisted reproductive technologies in Canada: 2005 results from the Canadian Assisted Reproductive Technologies Register Assisted reproductive technologies in Canada: 2005 results from the Canadian Assisted Reproductive Technologies Register Joanne Gunby, M.Sc., a Francxois Bissonnette, M.D., b Clifford Librach, M.D., c

More information

Reproductive Technology. Chapter 21

Reproductive Technology. Chapter 21 Reproductive Technology Chapter 21 Assisted Reproduction When a couple is sub-fertile or infertile they may need Assisted Reproduction to become pregnant: Replace source of gametes Sperm, oocyte or zygote

More information

OHTAC Recommendation. In Vitro Fertilization and Multiple Pregnancies

OHTAC Recommendation. In Vitro Fertilization and Multiple Pregnancies OHTAC Recommendation In Vitro Fertilization and Multiple Pregnancies October 19, 2006 The Ontario Health Technology Advisory Committee (OHTAC) met on October 19, 2006 and reviewed the health technology

More information

Preimplantation Genetic Diagnosis (PGD) for Fanconi Anemia and HLA matching

Preimplantation Genetic Diagnosis (PGD) for Fanconi Anemia and HLA matching Preimplantation Genetic Diagnosis (PGD) for Fanconi Anemia and HLA matching Andria G. Besser, BEd, MS, CGC Licensed Genetic Counselor Reproductive Genetics Institute Chicago, IL Outline PGD overview In

More information

Medical Policy Preimplantation Genetic Testing

Medical Policy Preimplantation Genetic Testing Medical Policy Preimplantation Genetic Testing Table of Contents Policy: Commercial Coding Information Information Pertaining to All Policies Policy: Medicare Description References Authorization Information

More information

European IVF Monitoring (EIM) Year: 2010

European IVF Monitoring (EIM) Year: 2010 European IVF Monitoring (EIM) Year: 2010 Name of country: Poland Name and full address of contact person: Professor Rafal Kurzawa, MD PhD Fertility and Sterility Special Interest Group Polish Gynaecological

More information

FERTILITY AND AGE. Introduction. Fertility in the later 30's and 40's. Am I fertile?

FERTILITY AND AGE. Introduction. Fertility in the later 30's and 40's. Am I fertile? FERTILITY AND AGE Introduction Delaying pregnancy is a common choice for women in today's society. The number of women in their late 30s and 40s attempting pregnancy and having babies has increased in

More information

Center for Women s Reproductive Care at Columbia University

Center for Women s Reproductive Care at Columbia University Center for Women s Reproductive Care at Columbia University Oocyte Recipients Greetings, Thank you for your interest in the Center for Women s Reproductive Care at Columbia University. We hope that the

More information

Preimplantation Genetic Diagnosis. Evaluation for single gene disorders

Preimplantation Genetic Diagnosis. Evaluation for single gene disorders Preimplantation Genetic Diagnosis Evaluation for single gene disorders What is Preimplantation Genetic Diagnosis? Preimplantation genetic diagnosis or PGD is a technology that allows genetic testing of

More information

European IVF Monitoring (EIM) Year: 2008

European IVF Monitoring (EIM) Year: 2008 European IVF Monitoring (EIM) Year: 2008 Name of country POLAND Name and full address of contact person. professor Rafal Kurzawa MD PhD Fertility and Sterility Special Interest Group Polish Gynaecological

More information

Consultations & other investigations

Consultations & other investigations Pricelist Please note as part of pre-treatment consultations, you may be required to have blood tests performed, the costs of which are not included in the treatment cycles. These costs are outlined below.

More information

IVF OVERVIEW. Tracy Telles, M.D.

IVF OVERVIEW. Tracy Telles, M.D. IVF OVERVIEW By Tracy Telles, M.D. Dr. Hendler: Hello and welcome to KP Healthcast. I m your host Dr. Peter Hendler and today our guest is Dr. Tracy Telles. Dr. Telles is an IVF physician in Kaiser Walnut

More information

CHROMOSOMES Dr. Fern Tsien, Dept. of Genetics, LSUHSC, NO, LA

CHROMOSOMES Dr. Fern Tsien, Dept. of Genetics, LSUHSC, NO, LA CHROMOSOMES Dr. Fern Tsien, Dept. of Genetics, LSUHSC, NO, LA Cytogenetics is the study of chromosomes and their structure, inheritance, and abnormalities. Chromosome abnormalities occur in approximately:

More information

CONSENT TO PARTICIPATE IN THE IN VITRO FERTILIZATION-EMBRYO TRANSFER PROGRAM

CONSENT TO PARTICIPATE IN THE IN VITRO FERTILIZATION-EMBRYO TRANSFER PROGRAM CONSENT TO PARTICIPATE IN THE IN VITRO FERTILIZATION-EMBRYO TRANSFER PROGRAM I, after consultation with my physician, request to participate in the In Vitro Fertilization (IVF)-Embryo Transfer (ET) procedures

More information

University Hospitals Coventry and Warwickshire NHS Trust. Centre for Reproductive Medicine. We Care. We Achieve. We Innovate.

University Hospitals Coventry and Warwickshire NHS Trust. Centre for Reproductive Medicine. We Care. We Achieve. We Innovate. University Hospitals Coventry and Warwickshire NHS Trust Centre for Reproductive Medicine We Care. We Achieve. We Innovate. Introduction We were the first NHS Hospital in the West Midlands to set up a

More information

Clinical Reference Group Quality & Safety Committee Governing Body. Policy Screened

Clinical Reference Group Quality & Safety Committee Governing Body. Policy Screened Fertility Policy 1 SUMMARY This policy is intended to support individuals and couples who want to become parents but who have a possible pathological problem (physical or psychological) leading to them

More information

PICSI Sperm Selection Device Instructions for Use

PICSI Sperm Selection Device Instructions for Use PICSI Sperm Selection Device Instructions for Use Manufacturer: Biocoat, Inc., 211 Witmer Rd., Horsham, PA 19044 USA Distributor: MidAtlantic Diagnostics, Inc., Telephone: 856-762-2000, www.midatlanticdiagnostics.com

More information

Illinois Insurance Facts Illinois Department of Financial and Professional Regulation Division of Insurance

Illinois Insurance Facts Illinois Department of Financial and Professional Regulation Division of Insurance Illinois Insurance Facts Illinois Department of Financial and Professional Regulation Division of Insurance Insurance Coverage for Infertility Treatment Revised November 2004 Infertility is a condition

More information

REPRODUCTIVE MEDICINE AND INFERTILITY ASSOCIATES Woodbury Medical Arts Building 2101 Woodwinds Drive Woodbury, MN 55125 (651) 222-6050

REPRODUCTIVE MEDICINE AND INFERTILITY ASSOCIATES Woodbury Medical Arts Building 2101 Woodwinds Drive Woodbury, MN 55125 (651) 222-6050 REPRODUCTIVE MEDICINE AND INFERTILITY ASSOCIATES Woodbury Medical Arts Building 2101 Woodwinds Drive Woodbury, MN 55125 (651) 222-6050 RECIPIENT COUPLE INFORMED CONSENT AND AUTHORIZATION FOR IN VITRO FERTILIZATION

More information

Male Infertility and Intracytoplasmic Sperm Injection (ICSI) in the Middle East

Male Infertility and Intracytoplasmic Sperm Injection (ICSI) in the Middle East Male Infertility and Intracytoplasmic Sperm Injection (ICSI) in the Middle East Marcia C. Inhorn The Male Infertility Problem 1 Infertility is the inability to conceive after 12 months of regular, unprotected

More information

The following chapter is called "Preimplantation Genetic Diagnosis (PGD)".

The following chapter is called Preimplantation Genetic Diagnosis (PGD). Slide 1 Welcome to chapter 9. The following chapter is called "Preimplantation Genetic Diagnosis (PGD)". The author is Dr. Maria Lalioti. Slide 2 The learning objectives of this chapter are: To learn the

More information

Final Version Two (Sept 2014) Eastern Cheshire Clinical Commissioning Group NHS Funded Treatment for Subfertility Policy

Final Version Two (Sept 2014) Eastern Cheshire Clinical Commissioning Group NHS Funded Treatment for Subfertility Policy Final Version Two (Sept 2014) Eastern Cheshire Clinical Commissioning Group NHS Funded Treatment for Subfertility Policy NHS FUNDED TREATMENT FOR SUBFERTILITY ELIGIBILITY CRITERIA Table of Contents 1.

More information

Fast Track to IVF. Objectives

Fast Track to IVF. Objectives Disclosure statement: Richard H. Reindollar, M.D. has no relevant financial relationships with any manufacturers of pharmaceuticals, laboratory supplies, or medical devices. Fast Track to IVF Richard H.

More information

IN VITRO FERTILISATION IVF and ICSI

IN VITRO FERTILISATION IVF and ICSI IN VITRO FERTILISATION IVF and ICSI Page 1 of 7 WHAT ARE IVF and ICSI? IVF is short for in vitro fertilisation which means fertilisation outside the body. It usually involves stimulation of the ovaries

More information

Acupuncture Treatment For Infertile Women Undergoing Intracytoplasmic Sperm injection

Acupuncture Treatment For Infertile Women Undergoing Intracytoplasmic Sperm injection Acupuncture Treatment For Infertile Women Undergoing Intracytoplasmic Sperm injection Sandra L. Emmons, MD Phillip Patton, MD Source: Medical Acupuncture, A Journal For Physicians By Physicians Spring

More information

The following chapter is called "Follow-ups with a Positive or a Negative Pregnancy Test".

The following chapter is called Follow-ups with a Positive or a Negative Pregnancy Test. Slide 1 Welcome to chapter 7. The following chapter is called "Follow-ups with a Positive or a Negative Pregnancy Test". The author is Professor Pasquale Patrizio. Slide 2 This chapter has the following

More information

How To Get A Refund On An Ivf Cycle

How To Get A Refund On An Ivf Cycle 100% IVF Refund Program Community Hospital North Clearvista Dr. N Dr. David Carnovale and Dr. Jeffrey Boldt, along with everyone at Community Reproductive Endocrinology, are committed to providing you

More information

DOES ASSISTED REPRODUCTIVE TECHNOLOGY (ART) INCREASE THE RISK OF BIRTH DEFECTS? JOE LEIGH SIMPSON, M.D. SENIOR VICE PRESIDENT FOR RESEARCH AND GLOBAL PROGRAMS MARCH OF DIMES FOUNDATION WHITE PLAINS, NY,

More information

Lesbian Pregnancy: Donor Insemination

Lesbian Pregnancy: Donor Insemination Lesbian Pregnancy: Donor Insemination (Based on an article originally published in the American Fertility Association 2010 National Fertility and Adoption Directory. Much of this information will also

More information

NEXT APPLICATION DEADLINE: NOVEMBER 18, 2015

NEXT APPLICATION DEADLINE: NOVEMBER 18, 2015 BABY QUEST FOUNDATION, INC. - GRANT APPLICATION Baby Quest is a nonprofit organization granting financial assistance for infertility treatments such as egg freezing, egg and sperm donation, IUI, IVF, and

More information

Ethical issues in assisted reproductive technologies. Effy Vayena

Ethical issues in assisted reproductive technologies. Effy Vayena Ethical issues in assisted reproductive technologies Effy Vayena Assisted Reproductive Technologies (ART) All treatments or procedures that include the in vitro handling of human oocytes and human sperm

More information

Technological & Ethical Issues In Laboratory-Assisted Reproduction A Short History to Accompany the Lecture

Technological & Ethical Issues In Laboratory-Assisted Reproduction A Short History to Accompany the Lecture 1 Technological & Ethical Issues In Laboratory-Assisted Reproduction A Short History to Accompany the Lecture Richard Bronson, M.D. Professor of Obstetrics & Gynecology and Pathology The treatment of infertility

More information

Preimplantation genetic diagnosis new method of screening of 24 chromosomes with the Array CGH method...2

Preimplantation genetic diagnosis new method of screening of 24 chromosomes with the Array CGH method...2 August 2012 content 8 Preimplantation genetic diagnosis new method of screening of 24 chromosomes with the Array CGH method...2 Maintaining fertility new opportunities in GENNET...3 Hysteroscopy without

More information

Assisted Conception Policy. February 2016. Dr. Liz Saunders Cyril Haessig

Assisted Conception Policy. February 2016. Dr. Liz Saunders Cyril Haessig Assisted Conception Policy February 2016 Dr. Liz Saunders Cyril Haessig CONTENTS Executive Summary... 3 Policy outline... 5 Detailed criteria... 8-2 - ASSISTED CONCEPTION COMMISSIONING POLICY EXECUTIVE

More information

Authorized By: Holly C. Bakke, Commissioner, Department of Banking and Insurance.

Authorized By: Holly C. Bakke, Commissioner, Department of Banking and Insurance. INSURANCE DIVISION OF INSURANCE Actuarial Services Benefit Standards for Infertility Coverage Proposed New Rules: N.J.A.C. 11:4-54 Authorized By: Holly C. Bakke, Commissioner, Department of Banking and

More information

INFORMED CONSENT AND AUTHORIZATION FOR IN VITRO FERTILIZATION OF PREVIOUSLY CRYOPRESERVED OOCYTES

INFORMED CONSENT AND AUTHORIZATION FOR IN VITRO FERTILIZATION OF PREVIOUSLY CRYOPRESERVED OOCYTES INFORMED CONSENT AND AUTHORIZATION FOR IN VITRO FERTILIZATION OF PREVIOUSLY CRYOPRESERVED OOCYTES We, the undersigned, as patient and partner understand that we will be undergoing one or more procedures

More information

Balanced. translocations. rarechromo.org. Support and Information

Balanced. translocations. rarechromo.org. Support and Information Support and Information Rare Chromosome Disorder Support Group, G1, The Stables, Station Rd West, Oxted, Surrey. RH8 9EE Tel: +44(0)1883 723356 info@rarechromo.org I www.rarechromo.org Balanced Unique

More information

Commissioning Policy for In Vitro Fertilisation (IVF)/ Intracytoplasmic Sperm Injection (ICSI) within tertiary Infertility Services.

Commissioning Policy for In Vitro Fertilisation (IVF)/ Intracytoplasmic Sperm Injection (ICSI) within tertiary Infertility Services. East Midlands CCGs Commissioning Policy for In Vitro Fertilisation (IVF)/ Intracytoplasmic Sperm Injection (ICSI) within tertiary Infertility Services April 2014 CONTENTS Page 1. INTRODUCTION 3 2. GENERAL

More information

IVF MONEY-BACK PLAN IN PARTNERSHIP WITH

IVF MONEY-BACK PLAN IN PARTNERSHIP WITH IVF MONEY-BACK PLAN IN PARTNERSHIP WITH Programmes Refund Programme Up to 3 fresh cycles of IVF/ICSI and all frozen embryo transfers Available to women under 40 years old Medical Review required for all

More information

ART - - - - - IVF - NO.1 IVF - IVF

ART - - - - - IVF - NO.1 IVF - IVF The success of any ART laboratory depends on its IVF laboratory. The primary function of an ART laboratory is to provide an optimal environment for gametes and embryos. To set up an ART laboratory, the

More information

Transitioning from IVF practice to restorative reproductive medicine.

Transitioning from IVF practice to restorative reproductive medicine. Transitioning from IVF practice to restorative reproductive medicine. Tadeusz Wasilewski Białystok Białystok Medical University in Branicki Palace - town of the first in vitro in Poland Cathedral - Divine

More information

Tower Hamlets CCG Fertility policy

Tower Hamlets CCG Fertility policy Tower Hamlets CCG Fertility policy Approved December 2014 Introduction Tower Hamlets CCG is responsible for commissioning a range of health services including hospital, mental health and community services

More information

Etienne Van den Abbeel

Etienne Van den Abbeel Optimized i scoring at blastocyst t stage ESHRE SIG Embryology Course, Practical aspects of non-invasive selection of gametes, embryos and blastocysts in a modern IVF laboratory, Salzburg, 2011. Etienne

More information

In vitro fertilization is associated with an increase in major birth defects

In vitro fertilization is associated with an increase in major birth defects In vitro fertilization is associated with an increase in major birth defects Christine K. Olson, M.D., M.P.H., a Kim M. Keppler-Noreuil, M.D., b Paul A. Romitti, Ph.D., c William T. Budelier, c Ginny Ryan,

More information

Nordic Fertility Society. Quality Guide. Checklist for ART Clinic and ART laboratory

Nordic Fertility Society. Quality Guide. Checklist for ART Clinic and ART laboratory Nordic Fertility Society Quality Guide Checklist for ART Clinic and ART laboratory Yes, not-applicable, No CLINICAL CHECK LIST PATIENT INFORMATION Is there a printed patient information on: Ovarian Stimulation?

More information

The genetic screening of preimplantation embryos by comparative genomic hybridisation

The genetic screening of preimplantation embryos by comparative genomic hybridisation Vol. 11, Suppl. 3 51 The genetic screening of preimplantation embryos by comparative genomic hybridisation Maria V Traversa 1, James Marshall, Steven McArthur, Don Leigh Genea, Sydney, Australia Received:

More information

Fertility care for women diagnosed with cancer

Fertility care for women diagnosed with cancer Saint Mary s Hospital Department of Reproductive Medicine Fertility care for women diagnosed with cancer Information For Patients INF/DRM/NUR/16 V1/01/11/2013 1 2 Contents Page Overview 4 Our Service 4

More information

Fertility Facts and Figures 2008

Fertility Facts and Figures 2008 Fertility Facts and Figures 2008 Contents About these statistics... 2 Accessing our data... 2 The scale of fertility problems... 3 Treatment abroad... 3 Contacts regarding this publication... 3 Latest

More information

Pregnancy Outcomes After Assisted Reproductive Technology

Pregnancy Outcomes After Assisted Reproductive Technology JOINT SOGC CFAS GUIDELINE JOINT SOGC CFAS GUIDELINE No 173, March 2006 Pregnancy Outcomes After Assisted Reproductive Technology This guideline has been reviewed by the Genetics Committee and the Reproductive

More information

Preimplantation genetic screening (PGS)

Preimplantation genetic screening (PGS) Preimplantation genetic screening (PGS) Dagan Wells Reprogenetics UK In vitro fertilization (IVF) A highly successful medical intervention Infertility treatment revolutionized Estimated that >5 million

More information

Review Article Is ICSI Risky?

Review Article Is ICSI Risky? Obstetrics and Gynecology International Volume 2013, Article ID 473289, 6 pages http://dx.doi.org/10.1155/2013/473289 Review Article Is ICSI Risky? May Y. W. Wong 1 and William L. Ledger 1,2 1 School of

More information

Methods for improvement of the success rate of artificial insemination with donor semen

Methods for improvement of the success rate of artificial insemination with donor semen INTERNATIONAL JOURNAL OFANDROLOGY 9 (1986) 14-2 Departments of Internul Medicine and Obstetrics, State University Hospital, Gent, Belgium Methods for improvement of the success rate of artificial insemination

More information

Midland Fertility Services Blastocyst Transfer

Midland Fertility Services Blastocyst Transfer Midland Fertility Services Blastocyst Transfer Building futures, transforming lives What is a blastocyst? When a sperm fertilises an egg the resulting embryo develops from the original single cell into

More information

Informed Consent Packet - In Vitro Fertilization (IVF)

Informed Consent Packet - In Vitro Fertilization (IVF) Center for Reproductive Medicine (CRM) Informed Consent Packet - In Vitro Fertilization (IVF) This packet contains the required IVF treatment consent documents. Please read, consider and, if you agree,

More information

Assignment Discovery Online Curriculum

Assignment Discovery Online Curriculum Assignment Discovery Online Curriculum Lesson title: In Vitro Fertilization Grade level: 9-12, with adaptation for younger students Subject area: Life Science Duration: Two class periods Objectives: Students

More information

ICSI and Miscarriage - A Review

ICSI and Miscarriage - A Review Incidence of First Trimester Miscarriage among Women Undergoing ICSI According to Origin of Sperm for Male Factor and Non-male Factor ALKA GAHLOT*, ML SWARANKAR, RAVIKANT SONI ABSTRACT Prior to the development

More information

Genetic methods for assessing embryo viability and improving IVF treatment

Genetic methods for assessing embryo viability and improving IVF treatment Genetic methods for assessing embryo viability and improving IVF treatment Prof. Dagan Wells, PhD, FRCPath Reprogenetics UK Points for discussion Diagnosis of inherited disorders in preimplantation embryos

More information

FREEDOM OF INFORMATION ACT 2000 Birmingham CrossCity CCG Ref: FOI/002790 IVF Funding Policy

FREEDOM OF INFORMATION ACT 2000 Birmingham CrossCity CCG Ref: FOI/002790 IVF Funding Policy Our Ref: FOI/002790 08 th August 2014 Bartholomew House 1 st Floor 142 Hagley Road Birmingham B16 9PA www.bhamcrosscityccg.nhs.uk Email: bham.crosscity@nhs.net Tel. 0121 255 0700 FREEDOM OF INFORMATION

More information

In Vitro Fertilization and Multiple Pregnancies

In Vitro Fertilization and Multiple Pregnancies Ontario Health Technology Assessment Series 2006; Vol. 6, No. 18 In Vitro Fertilization and Multiple Pregnancies An Evidence-Based Analysis October 2006 Medical Advisory Secretariat Ministry of Health

More information

Causes for unintentional childlessness

Causes for unintentional childlessness Causes for unintentional childlessness We can define fertility as the inability to become pregnant after one year of regular sexual intercourse. The causes of infertility are evenly distributed among men

More information

Consent for Treatment

Consent for Treatment IVF_Consent_Booklet_Web_5.2015_IVFNE:IVFConsentBook.v2 5/28/2015 11:21 AM Page 1 Assisted Reproduction In Vitro Fertilization Intracytoplasmic Sperm Injection Assisted Hatching Embryo Cryopreservation

More information

London Fertility Centre Price List

London Fertility Centre Price List London Fertility Centre Price List Fertility Testing Packages Standard Female fertility testing package AMH Ultrasound scan 15 minute doctor consultation to discuss your results Premium Female fertility

More information

Article Wide range of chromosome abnormalities in the embryos of young egg donors

Article Wide range of chromosome abnormalities in the embryos of young egg donors RBMOnline - Vol 12. No 3. 2006 340-346 Reproductive BioMedicine Online; www.rbmonline.com/article/2050 on web 12 January 2006 Article Wide range of chromosome abnormalities in the embryos of young egg

More information

Consent for In Vitro Fertilization

Consent for In Vitro Fertilization Consent for In Vitro Fertilization Print Patient s Name Print Partner s Name We (I), the undersigned, request, authorize and consent to the procedure of In Vitro Fertilization (IVF) and Embryo Transfer

More information

Consent for Frozen Donor Oocyte In Vitro Fertilization and Embryo Transfer (Recipient)

Consent for Frozen Donor Oocyte In Vitro Fertilization and Embryo Transfer (Recipient) Name of Patient: Name of Partner: We, the Patient and Partner (if applicable) named above, are each over the age of twenty-one (21) years. By our signatures below, I/we request and authorize the performance

More information

How to choose an IVF clinic and understand success rates: Questions to ask when choosing an IVF clinic.

How to choose an IVF clinic and understand success rates: Questions to ask when choosing an IVF clinic. Australia s National Infertility Network How to choose an IVF clinic and understand success rates: Questions to ask when choosing an IVF clinic. updated 26 05 2015 20 The information contained here is

More information

IVF. IVF: The Success of Technology. Recent Advances in Assisted Reproductive Technologies 10/20/2007

IVF. IVF: The Success of Technology. Recent Advances in Assisted Reproductive Technologies 10/20/2007 Obstetrics and Gynecology Update: What Does the Evidence Tell Us? 1 In Vitro Fertilization () 2 Recent Advances in Assisted Reproductive Technologies Shehua Shen, M.D., ELD (ABB) Assistant Professor Department

More information

Our laboratory guide for you and your embryos

Our laboratory guide for you and your embryos Lab guide Our laboratory guide for you and your embryos We hope that this guide will give you a better understanding of the journey you and your embryos will take through our laboratory, and help you contribute

More information

OUR IVF/ICSI PROGRAMME

OUR IVF/ICSI PROGRAMME OUR IVF/ICSI PROGRAMME The Manzanera Fertility Clinic has designed a simple fertility programme that aims to be convenient for couples living outside of Spain while maximising your chances of success.

More information

Pregnancy rates are higher with intracytoplasmic morphologically selected sperm injection than with conventional intracytoplasmic injection

Pregnancy rates are higher with intracytoplasmic morphologically selected sperm injection than with conventional intracytoplasmic injection FERTILITY AND STERILITY VOL. 80, NO. 6, DECEMBER 2003 Copyright 2003 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. Pregnancy rates are higher

More information

Endometriosis, Fertility and Pregnancy

Endometriosis, Fertility and Pregnancy This leaflet covers endometriosis and fertility. It provides information for women who have been diagnosed with endometriosis who would like to know if and how this can affect their fertility, and for

More information

In Vitro Fertilization

In Vitro Fertilization Patient Education In Vitro Fertilization What to expect This handout describes how to prepare for and what to expect when you have in vitro fertilization. It provides written information about this process,

More information

Shyam S. R. Allamaneni, M.D., Ilian Bandaranayake, M.D., and Ashok Agarwal, Ph.D., HCLD

Shyam S. R. Allamaneni, M.D., Ilian Bandaranayake, M.D., and Ashok Agarwal, Ph.D., HCLD MALE FACTOR FERTILITY AND STERILITY VOL. 82, NO. 3, SEPTEMBER 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. Use of semen

More information

Assisted Reproductive Technologies

Assisted Reproductive Technologies Assisted Reproductive Technologies Last Review Date: December 10, 2015 Number: MG.MM.ME.34j Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary

More information

Gestational Carrier / Directed Donor In-Vitro Fertilization Handbook

Gestational Carrier / Directed Donor In-Vitro Fertilization Handbook Gestational Carrier / Directed Donor In-Vitro Fertilization Handbook William F. Ziegler, D.O. Medical Director Scott Kratka, ELD, TS Embryology Laboratory Director Lauren F. Lucas, PA-C, M.S Physician

More information

Ali Ahmady, PhD, MSc, HCLD 1441 Hemingford Lane Mississauga, ON, L5N 7Y7 Tel: 905 696 0985 Cell:416 399 8736 ali_ahmady@yahoo.com

Ali Ahmady, PhD, MSc, HCLD 1441 Hemingford Lane Mississauga, ON, L5N 7Y7 Tel: 905 696 0985 Cell:416 399 8736 ali_ahmady@yahoo.com Ali Ahmady, PhD, MSc, HCLD 1441 Hemingford Lane Mississauga, ON, L5N 7Y7 Tel: 905 696 0985 Cell:416 399 8736 ali_ahmady@yahoo.com Embryologist with more than 16 years experience in Reproductive biology

More information